跳至主要内容
临床试验/NCT01052935
NCT01052935已完成1 期

A Phase I Extension Study to Assess the Long-Term Persistence of GBS Serotype Ia Antibodies in Women Previously Immunized With a GBS Ia Crm-Glycoconjugate Vaccine

Novartis1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2010年1月1日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
发起方
Novartis
入组人数
50
试验地点
1
主要终点
Antibody (Ab) response data at 24-months after the last injection given in study V98P1 GMCs, GMRs and associated 95% confidence intervals will also be determined

研究概览

简要总结

This study looks at the body's immune responses to a GBS vaccine 2 years after the orginal vaccine(s) were given in the V98P1 study. Blood will be drawn and evaluated for GBS antibody levels.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
20 Years 至 42 Years(Adult)
性别
Female
接受健康志愿者
是

入选标准

  • •Individuals who have given written consent.
  • •Individuals who participated in V98P1 and received the complete schedule of vaccinations.

排除标准

  • •Individuals who have not given written consent.
  • •Subjects who did not receive the complete schedule of vaccination in V98P1.

研究组 & 干预措施

Arm 1

No Intervention

This is a phlebotomy study.

干预措施: Group B streptococcus (GBS) vaccine (Biological)

结局指标

主要结局

Antibody (Ab) response data at 24-months after the last injection given in study V98P1 GMCs, GMRs and associated 95% confidence intervals will also be determined

时间窗: 24- months post last injection from V98P1

次要结局

未报告次要终点

研究者

发起方
Novartis
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

A Study to Assess the Persistence of a GBS Antibody... | 临床试验